Immunovant (Nasdaq:IMVT) - Aktienkurs, Nachrichten und Analyse

IMVT Aktienübersicht

Immunovant, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt monoklonale Antikörper für die Behandlung von Autoimmunerkrankungen. Mehr Details

IMVT grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 75.52%

Analysten sind sich einig, dass der Aktienkurs um 70.3%

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Signifikante Insiderverkäufe in den letzten 3 Monaten

Immunovant, Inc. Wettbewerber

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.2b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

RayzeBio

NasdaqGM:RYZB

US$3.7b

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$3.8b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Immunovant
Historische Aktienkurse
Aktueller Aktienkurs	US$28.73
52-Wochen-Hoch	US$45.58
52-Wochen-Tief	US$24.61
Beta	0.71
11 Monat Veränderung	-4.07%
3 Monate Veränderung	-7.26%
1 Jahr Veränderung	-24.87%
33 Jahre Veränderung	281.54%
5 Jahre Veränderung	182.78%
Veränderung seit IPO	188.74%

Aktuelle Nachrichten und Updates

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Aktionärsrenditen

	IMVT	US Biotechs	US Markt
7D	9.8%	4.3%	1.6%
1Y	-24.9%	18.8%	32.3%

Rendite im Vergleich zur Industrie: IMVT unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 18.8% erzielte.

Rendite vs. Markt: IMVT hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 32.3 erzielte.

Preisvolatilität

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement	6.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: IMVT hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: IMVTDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	207	Pete Salzmann	immunovant.com

Immunovant, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt monoklonale Antikörper für die Behandlung von Autoimmunerkrankungen. Das Unternehmen entwickelt Batoclimab, einen neuartigen, vollständig humanen monoklonalen Antikörper, der auf den kristallisierbaren Rezeptor des neonatalen Fragments abzielt, zur Behandlung von Myasthenia gravis, Schilddrüsenerkrankungen, chronisch entzündlicher demyelinisierender Polyneuropathie, Morbus Basedow und warmer autoimmuner hämolytischer Anämie. Immunovant, Inc. hat seinen Sitz in New York, New York.

Immunovant, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Immunovant im Vergleich zum Marktanteil des Unternehmens?
IMVT grundlegende Statistiken
Marktanteil	US$3.99b
Gewinn(TTM)	-US$323.01m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-13.1x

Kurs-Gewinn-Verhältnis

Ist IMVT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IMVT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$323.01m
Umsatz	-US$323.01m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.20
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich IMVT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

IMVT Aktienübersicht

Belohnungen

Risikoanalyse

Immunovant, Inc. Wettbewerber

NasdaqGM:CRSP

US$4.2b

NasdaqGS:TPTX

US$3.8b

NasdaqGM:RYZB

US$3.7b

NasdaqGM:RYTM

US$3.8b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Recent updates

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Erträge & Einnahmen